ETFs CytomX Therapeutics, Inc.

CTMX

US23284F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
4.390 ^USD	+3.54%		-3.73%	+3.05%

Mar. 20	Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing	MT
Mar. 18	CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell	MT

ETFs positioned on CytomX Therapeutics, Inc.

Name		Varia. Jan 1.	Weight	AuM
VANGUARD US TOTAL MARKET SHARES INDEX ETF		-5.90%	0%	293,477 M€

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company